137 related articles for article (PubMed ID: 26200988)
1. PET-Directed Therapy for Hodgkin's Lymphoma.
Bishop G
N Engl J Med; 2015 Jul; 373(4):392. PubMed ID: 26200988
[No Abstract] [Full Text] [Related]
2. PET-Directed Therapy for Hodgkin's Lymphoma.
Radford J; Illidge T; Barrington S
N Engl J Med; 2015 Jul; 373(4):392. PubMed ID: 26200987
[No Abstract] [Full Text] [Related]
3. PET after chemotherapy identifies Hodgkin's lymphoma patients who can avoid radiotherapy.
Mayor S
BMJ; 2015 Apr; 350():h2190. PubMed ID: 25908591
[No Abstract] [Full Text] [Related]
4. Personalised approach to treating early Hodgkin's lymphoma.
Illidge T
BMJ; 2015 Jun; 350():h2927. PubMed ID: 26038281
[No Abstract] [Full Text] [Related]
5. Controversies in the treatment of early-stage Hodgkin's lymphoma.
Longo DL; Armitage JO
N Engl J Med; 2015 Apr; 372(17):1667-9. PubMed ID: 25901431
[No Abstract] [Full Text] [Related]
6. Escalated BEACOPP in advanced Hodgkin's lymphoma.
Casasnovas O; Coiffier B
Lancet; 2012 May; 379(9828):1767-8. PubMed ID: 22480757
[No Abstract] [Full Text] [Related]
7. PET-adapted salvage therapy for Hodgkin's lymphoma.
Laffon E; Marthan R
Lancet Oncol; 2015 May; 16(5):e197-8. PubMed ID: 25943059
[No Abstract] [Full Text] [Related]
8. PET-adapted salvage therapy in Hodgkin's lymphoma.
Tirelli U; Spina M
Lancet Oncol; 2015 Mar; 16(3):239-40. PubMed ID: 25683849
[No Abstract] [Full Text] [Related]
9. PET-adapted salvage therapy for Hodgkin's lymphoma--authors' reply.
Schöder H; Moskowitz CH; Moskowitz AJ
Lancet Oncol; 2015 May; 16(5):e198. PubMed ID: 25943060
[No Abstract] [Full Text] [Related]
10. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
Engert A; Haverkamp H; Kobe C; Markova J; Renner C; Ho A; Zijlstra J; Král Z; Fuchs M; Hallek M; Kanz L; Döhner H; Dörken B; Engel N; Topp M; Klutmann S; Amthauer H; Bockisch A; Kluge R; Kratochwil C; Schober O; Greil R; Andreesen R; Kneba M; Pfreundschuh M; Stein H; Eich HT; Müller RP; Dietlein M; Borchmann P; Diehl V; ; ;
Lancet; 2012 May; 379(9828):1791-9. PubMed ID: 22480758
[TBL] [Abstract][Full Text] [Related]
11. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
12. Fine-Tuning the Treatment of Hodgkin's Lymphoma.
Bartlett NL
N Engl J Med; 2016 Jun; 374(25):2490-2. PubMed ID: 27332908
[No Abstract] [Full Text] [Related]
13. RAPID Trial Demonstrates Low Positive Predictive Value of Interim FDG-PET in Early-stage Hodgkin Lymphoma After Three Cycles of ABVD.
Adams HJ; Kwee TC
J Pediatr Hematol Oncol; 2016 Mar; 38(2):165. PubMed ID: 26583613
[No Abstract] [Full Text] [Related]
14. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. In Reply to Adams and Kwee.
Simontacchi G; Filippi AR; Ciammella P; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):725-6. PubMed ID: 26461018
[No Abstract] [Full Text] [Related]
15. Early-stage favorable Hodgkin's lymphoma: is chemotherapy alone sufficient?
Ozsahin M; Ozsahin H
J Clin Oncol; 2010 Nov; 28(32):e668-9; author reply e670. PubMed ID: 20713868
[No Abstract] [Full Text] [Related]
16. Finding the balance in pediatric Hodgkin's lymphoma.
Donaldson SS
J Clin Oncol; 2012 Sep; 30(26):3158-9. PubMed ID: 22649142
[No Abstract] [Full Text] [Related]
17. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. In Regard to Simontacchi et al.
Adams HJ; Kwee TC
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):724-5. PubMed ID: 26461017
[No Abstract] [Full Text] [Related]
18. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
19. Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat.
Yahalom J
Leuk Lymphoma; 2007 Sep; 48(9):1667-9. PubMed ID: 17786699
[No Abstract] [Full Text] [Related]
20. Chemotherapy alone for early-stage Hodgkin's lymphoma.
Straus DJ
N Engl J Med; 2012 Feb; 366(5):470-1. PubMed ID: 22149920
[No Abstract] [Full Text] [Related]
[Next] [New Search]
